Capstone Investment Advisors
PLRX icon

Capstone Investment Advisors’s Pliant Therapeutics PLRX Stock Holding History

Capstone Investment Advisors’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-22,711
Closed -$394K – 2336
2023
Q3 		$394K Buy
+22,711
New +$394K ﹤0.01% 1448

Other funds holding PLRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

Capstone Investment Advisors's PLRX Position: Q4 2023 in Review

Capstone Investment Advisors sold out of Pliant Therapeutics (PLRX) in Q4 2023, closing a stake of 22,711 shares — an estimated $394K sold.

Capstone Investment Advisors first reported a position in PLRX in Q3 2023 and held it in 1 quarter. The position peaked at $394K in Q3 2023. 134 funds tracked by Wall St. Rank hold PLRX as of Q4 2023.

  • Capstone Investment Advisors reported no remaining Pliant Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Capstone Investment Advisors sold 22,711 Pliant Therapeutics shares in Q4 2023, an estimated $394K.
  • Capstone Investment Advisors first reported a position in Pliant Therapeutics in Q3 2023 and held it in 1 quarter.
  • Capstone Investment Advisors's Pliant Therapeutics position peaked at $394K in Q3 2023.
  • 134 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q4 2023.

Based on Capstone Investment Advisors's 13F filing for Q4 2023, filed 12 Feb 2024.